Characterization of platelet factor 4 amino acids that bind pathogenic antibodies in heparin-induced thrombocytopenia
- PMID: 30582672
- DOI: 10.1111/jth.14369
Characterization of platelet factor 4 amino acids that bind pathogenic antibodies in heparin-induced thrombocytopenia
Erratum in
-
Corrigendum.J Thromb Haemost. 2019 Sep;17(9):1578. doi: 10.1111/jth.14599. J Thromb Haemost. 2019. PMID: 31479188 No abstract available.
Abstract
Essentials Many patients produce antibodies but few lead to heparin-induced thrombocytopenia (HIT). Pathogenic epitopes are difficult to identify as HIT antibodies are polyclonal and polyspecific. KKO binding to platelet factor 4 (PF4) depends on 13 amino acids, three of which are newly observed. Five amino acids in PF4 can help distinguish pathogenic from non-pathogenic antibodies. SUMMARY: Background Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction that results in thrombocytopenia and, in some patients, thrombotic complications. HIT is mediated by antibodies that bind to complexes of platelet factor 4 (PF4) and heparin. The antigenic epitopes of these anti-PF4/heparin antibodies have not yet been precisely defined, because of the polyspecific immune response that characterizes HIT. Objectives To identify PF4 amino acids essential for binding pathogenic HIT antibodies. Methods Alanine scanning mutagenesis was utilized to produce 70 single point mutations of PF4. Each PF4 mutant was used in an enzyme immunoassay (EIA) to test their capacity to bind a platelet-activating murine monoclonal anti-PF4/heparin antibody (KKO) and HIT patient sera (n = 9). Results and Conclusions We identified 13 amino acids that were essential for binding KKO because they directly affected either the binding site or the antigenic conformation of PF4. We also identified 10 amino acids that were required for the binding of HIT patient sera and five of these amino acids were required for binding both KKO and the HIT patient sera. The 10 amino acids required for binding HIT sera were further tested to differentiate pathogenic HIT antibodies (platelet activating, n = 45) and non-pathogenic antibodies (EIA-positive but not platelet activating, n = 28). We identified five mutations of PF4 that were recognized to be essential for binding pathogenic HIT antibodies. Using alanine scanning mutagenesis, we characterized possible binding sites of pathogenic HIT antibodies on PF4.
Keywords: CXCL4; heparin; heparin-induced thrombocytopenia; platelet factor 4; thrombocytopenia; thrombosis.
© 2018 International Society on Thrombosis and Haemostasis.
Similar articles
-
Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies.Blood. 2000 Mar 1;95(5):1533-40. Blood. 2000. PMID: 10688805
-
Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody.Blood. 2002 Feb 15;99(4):1230-6. doi: 10.1182/blood.v99.4.1230. Blood. 2002. PMID: 11830470
-
5B9, a monoclonal antiplatelet factor 4/heparin IgG with a human Fc fragment that mimics heparin-induced thrombocytopenia antibodies.J Thromb Haemost. 2017 Oct;15(10):2065-2075. doi: 10.1111/jth.13786. Epub 2017 Sep 4. J Thromb Haemost. 2017. PMID: 28771917
-
Testing for heparin-induced thrombocytopenia antibodies.Transfus Med Rev. 2006 Oct;20(4):259-72. doi: 10.1016/j.tmrv.2006.05.001. Transfus Med Rev. 2006. PMID: 17008164 Review.
-
Laboratory Testing for Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia Antibodies: A Narrative Review.Semin Thromb Hemost. 2023 Sep;49(6):621-633. doi: 10.1055/s-0042-1758818. Epub 2022 Dec 1. Semin Thromb Hemost. 2023. PMID: 36455619 Free PMC article. Review.
Cited by
-
Structural Features and PF4 Functions that Occur in Heparin-Induced Thrombocytopenia (HIT) Complicated by COVID-19.Antibodies (Basel). 2020 Oct 10;9(4):52. doi: 10.3390/antib9040052. Antibodies (Basel). 2020. PMID: 33050376 Free PMC article. Review.
-
Platelet factor 4 induces bone loss by inhibiting the integrin α5-FAK-ERK pathway.Animal Model Exp Med. 2023 Dec;6(6):573-584. doi: 10.1002/ame2.12342. Epub 2023 Aug 11. Animal Model Exp Med. 2023. PMID: 37565509 Free PMC article.
-
Characteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S.Blood Adv. 2023 Jan 24;7(2):246-250. doi: 10.1182/bloodadvances.2022007336. Blood Adv. 2023. PMID: 35377937 Free PMC article. No abstract available.
-
Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT.Blood. 2022 Jul 7;140(1):73-77. doi: 10.1182/blood.2021014588. Blood. 2022. PMID: 35560046 Free PMC article.
-
SARS-CoV-2 spike-dependent platelet activation in COVID-19 vaccine-induced thrombocytopenia.Blood Adv. 2022 Apr 12;6(7):2250-2253. doi: 10.1182/bloodadvances.2021005050. Blood Adv. 2022. PMID: 34724709 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous